In recent years, systemic chemotherapy has significantly improved the prognosis of metastatic colorectal cancer (CRC); however, different patients have different responses to chemotherapeutics.
Dipeptidyl peptidase 9 (DPP9) is an enzyme in the dipeptidyl peptidase IV family that has been reported to increase drug sensitivity in acute myeloid leukemia. In this study, we examined the relationship between DPP9 expression and the prognosis of patients with CRC, as well as the role of DPP9 in anticancer drug resistance. Moreover, the effects of the DPP9 inhibitors talabostat and vildagliptin in CRC cell lines and primary cultured cells were assessed.
High expression of DPP9 was associated with worse prognosis in 196 patients with CRC. Cell viability was markedly inhibited in CRC cell lines transfected with DPP9 small interfering RNA or small hairpin RNA. Talabostat suppressed proliferation in CRC cell lines and primary cultured cells, and increased their sensitivity to chemotherapy. Vildagliptin, a DPP family inhibitor currently administered for diabetes, also increased the sensitivity of CRC cells to anticancer drugs.
DPP9 was a poor prognostic factor for CRC and could be a new therapeutic target, while vildagliptin could be used as a repositioned drug for CRC treatment.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
Matsuda T, Yamashita K, Hasegawa H, Oshikiri T, Hosono M, Higashino N, et al. Recent updates in the surgical treatment of colorectal cancer. Ann Gastroenterol Surg. 2018;2:129–36.
Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil–leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209–14.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.
Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:2311–19.
Ajami K, Abbott CA, McCaughan GW, Gorrell MD. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta. 2004;1679:18–28.
Abbott CA, Yu DM, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem. 2000;267:6140–50.
Olsen C, Wagtmann N. Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV. Gene. 2002;299:185–93.
Rummey C, Metz G. Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site. Proteins. 2007;66:160–71.
Qi SY, Riviere PJ, Trojnar J, Junien JL, Akinsanya KO. Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases. Biochem J. 2003;373:179–89.
Pitman MR, Sulda ML, Kuss B, Abbott CA. Dipeptidyl peptidase 8 and 9—guilty by association? Front Biosci (Landmark Ed). 2009;14:3619–33.
Zhang H, Chen Y, Keane FM, Gorrell MD. Advances in understanding the expression and function of dipeptidyl peptidase 8 and 9. Mol Cancer Res. 2013;11:1487–96.
Johnson DC, Taabazuing CY, Okondo MC, Chui AJ, Rao SD, Brown FC, et al. DPP8/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia. Nat Med. 2018;24:1151–56.
Tang Z, Li J, Shen Q, Feng J, Liu H, Wang W, et al. Contribution of upregulated dipeptidyl peptidase 9 (DPP9) in promoting tumoregenicity, metastasis and the prediction of poor prognosis in non-small cell lung cancer (NSCLC). Int J Cancer. 2017;140:1620–32.
Smebye ML, Agostini A, Johannessen B, Thorsen J, Davidson B, Trope CG, et al. Involvement of DPP9 in gene fusions in serous ovarian carcinoma. BMC Cancer. 2017;17:642.
Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005;54:2988–94.
Jiaang WT, Chen YS, Hsu T, Wu SH, Chien CH, Chang CN, et al. Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8. Bioorg Med Chem Lett. 2005;15:687–91.
Waumans Y, Baerts L, Kehoe K, Lambeir AM, De Meester I. The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis. Front Immunol. 2015;6:387.
Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:4888–94.
Burkey BF, Hoffmann PK, Hassiepen U, Trappe J, Juedes M, Foley JE. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab. 2008;10:1057–61.
Amritha CA, Kumaravelu P, Chellathai DD. Evaluation of anti cancer effects of DPP-4 inhibitors in colon cancer—an invitro Study. J Clin Diagn Res. 2015;9:FC14–6.
Spagnuolo PA, Hurren R, Gronda M, MacLean N, Datti A, Basheer A, et al. Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide’s anti-leukemic activity. Leukemia. 2013;27:1236–44.
Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23:1–34.
Fujino S, Ito A, Ohue M, Yasui M, Mizushima T, Doki Y, et al. Phenotypic heterogeneity of 2D organoid reflects clinical tumor characteristics. Biochem Biophys Res Commun. 2019;513:332–9.
Sikandar SS, Pate KT, Anderson S, Dizon D, Edwards RA, Waterman ML et al. NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res. 2010;70(4):1469–78.
Fujino S, Myoshi N, Saso K, Sasaki M, Ishikawa S, Takahashi Y, et al. The inflammation-nutrition score supports the prognostic prediction of the TNM stage for colorectal cancer patients after curative resection. Surg Today. 2020;50(2):163–70.
Yao TW, Kim WS, Yu DM, Sharbeen G, McCaughan GW, Choi KY, et al. A novel role of dipeptidyl peptidase 9 in epidermal growth factor signaling. Mol Cancer Res. 2011;9:948–59.
The authors would like to thank Ms. Aya Ito for special technical assistance regarding sample preparation.
Kazuhiro Saso, Norikatsu Myoshi, Shiki Fujino, Masaru Sasaki, Masayoshi Yasui, Masayuki Ohue, Takayuki Ogino, Hidekazu Takahashi, Mamoru Uemura, Chu Matsuda, Tsunekazu Mizushima, Yuichiro Doki, and Hidetoshi Eguchi declare no competing financial interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplementary Figure 3 Overall survival based on DPP9 mRNA expression in CRC patients with postoperative recurrence. The 5-year OS was lower in patients with high DPP9 expression compared to those with low expression. DPP9, dipeptidyl peptidase 9; GAPDH; glyceraldehyde-3-phosphate dehydrogenase; CRC, colorectal cancer; OS, overall survival (PNG 170 kb)
Supplementary Figure 4 DPP9 expression is increased in CRC and high expression is associated with worse overall survival in patients with adjuvant chemotherapy. In patient who were treated by adjuvant chemotherapy, the high-expression group had significantly lower 5-years OS than the low-expression group (P = 0.034), but there is no significant difference in disease-free survival between the two groups (P = 0.428). DPP9, dipeptidyl peptidase 9; GAPDH; glyceraldehyde-3-phosphate dehydrogenase; CRC, colorectal cancer; OS, overall survival (PNG 103 kb)
Supplementary Figure 5 In patient who had recurrence and were treated by chemotherapy, the high-expression group had lower OS than the low-expression group (P = 0.067). DPP9, dipeptidyl peptidase 9; GAPDH; glyceraldehyde-3-phosphate dehydrogenase; CRC: colorectal cancer; OS, overall survival (PNG 135 kb)
About this article
Cite this article
Saso, K., Miyoshi, N., Fujino, S. et al. Dipeptidyl Peptidase 9 Increases Chemoresistance and is an Indicator of Poor Prognosis in Colorectal Cancer. Ann Surg Oncol 27, 4337–4347 (2020). https://doi.org/10.1245/s10434-020-08729-7